DaVita Inc. (DVA) fair value analysis
S&P 500 · Updated 2026-10-19
DVA price how computed
Forward Fair Value verdict
UndervaluedDVA is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $179.25
- Sector
- Healthcare
- 12-month range
- $103.87–$240.96
- Market cap
- $11.4B
- From 52-week high
- -25.6%
- Shares outstanding
- 63.8M
- Rank in Healthcare by discount to fair value
- #29 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
DaVita Inc. is a healthcare company that provides dialysis services and related treatments for patients with chronic kidney disease and end-stage renal disease. The company operates dialysis centers and related care facilities across the United States and in several international markets.
DVA currently ranks #29 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $11.4B
- P/E (trailing)
- 14x
- Revenue (TTM)
- $14B
- Net margin
- 6.0%
- EPS (TTM)
- $12.80
- Gross margin
- 32.7%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 4.6%
- Shares outstanding
- 63.8M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 58 · neutral
- 50-day average
- $180.49
- 200-day average
- $173.37
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+0.2%)
2026-03 ▲ beat (+23.2%)
2025-12 ▲ beat (+6.6%)
2025-09 ▼ miss (-20.8%)
2025-06 ▲ beat (+7.3%)
2025-03 ▼ miss (-1.0%)
2024-12 ▲ beat (+5.2%)
2024-09 ▼ miss (-4.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 4 hold · 1 sell (8 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $220
- Target vs last price
- +22.7%
What our data shows for DVA
- Our model validated 17 trailing price-to-earnings windows for DVA, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $103.87–$240.96.
- The 14-day relative strength index sits at a neutral 58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for DVA
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent DVA news
TickrTrends' derived news-sentiment signal for DVA is currently leaning positive, computed from recent coverage.
- HHS Kidney Care Plan Raises Concerns for DaVita (DVA) Amid Positive Analyst Outlook (gurufocus.com, 2026-10-21)
TickrTrends take: The HHS kidney care plan introduces regulatory uncertainty that could pressure DVA's dialysis business, a core revenue driver for the company. Despite analyst optimism about other aspects of the business, investors focused on valuation should monitor how policy changes might affect reimbursement rates and patient volumes, which are critical metrics for assessing whether the current undervalued designation holds. The healthcare sector's sensitivity to regulatory shifts means that DVA's valuation could shift meaningfully depending on how the kidney care initiative develops and its ultimate impact on the company's operational margins. - DaVita Inc. (DVA) Shares Drop Over 6% Amid New Kidney Care Plan Announcement (gurufocus.com, 2026-10-20)
TickrTrends take: DaVita's recent share decline creates a potential disconnect between market reaction and TickrTrends' undervalued assessment, suggesting investors may be overweighting near-term uncertainty around the kidney care plan announcement. A valuation-focused investor should monitor whether this pullback reflects genuine deterioration in the company's fundamental earnings power or represents an overreaction that could present a valuation opportunity in the healthcare sector. The divergence between the stock's price movement and the valuation signal warrants attention to how the market reassesses DVA's competitive positioning and profitability as details around the new kidney care plan emerge. - DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA) (seekingalpha.com, 2026-10-09)
TickrTrends take: DaVita's recent 25% price decline has brought its valuation metrics into territory that may attract value-oriented investors, aligning with TickrTrends' current undervalued assessment within the Healthcare sector. The company's buyback activity historically signals management confidence in pricing, and a cheaper stock price combined with share repurchases could influence earnings per share dynamics that warrant monitoring. Valuation-focused readers should track whether the company maintains its capital allocation strategy at these lower levels and how that affects shareholder returns relative to sector peers.
More DVA news
- DaVita Inc (DVA) Shares Fall 4.6% -- What GF Score of 92 Tells Investors (gurufocus.com, 2026-09-24)
- 3 Surging Stocks That Don’t Need the AI Boom to Keep Winning (finance.yahoo.com, 2026-09-21)
What people are saying
Follow the DVA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for DVA in the Healthcare sector show a shift this week, with the sector discount rank moving from #40 to #45. This change reflects a modest decline in DVA's relative valuation position within the sector rankings. The current valuation verdict remains Undervalued.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is DVA stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), DVA is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is DVA's TickrTrends verdict?
DVA's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does DVA compare to other Healthcare stocks?
DVA ranks #29 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is DVA overbought or oversold?
DVA's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does DVA report earnings next?
DVA's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does DVA usually beat earnings estimates?
Over its last 8 reported quarters DVA beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about DVA?
Of 8 analysts covering DVA, 3 rate it a buy, 4 a hold and 1 a sell - hold-leaning, with a consensus price target of $220 (+22.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
DVA vs ABT · DVA vs AMPH · DVA vs CI · DVA vs DNLI · DVA vs EW